Australia’s largest medical research organisation has advised puberty blockers are appropriate for the gender-affirming care of children in certain circumstances, after a year-long review of international evidence.

The federal government last year commissioned the commonwealth-funded National Health and Medical Research Council (NHMRC) to develop the advice in response to bans in Queensland and Northern Territory public hospitals imposed by their governments.

The New Zealand government later followed suit despite widespread opposition in the health sector and warnings that the bans would harm children.

The NHMRC’s interim national clinical practice guidelines released on Monday, which advise conditional use of puberty suppressants for children, could put pressure on state and territory governments to consider their positions.

The council explicitly rejected alternative approaches to gender-affirming care proposed by opponents of the approach – such as the “wait and see” model – as a form of withholding care for children which it stated “can affect the young person’s physical and mental health, wellbeing, and ability to function”.

Puberty blockers are a class of drugs used to stop the body producing oestrogen and testosterone.

Hormone replacement therapy is a treatment that replaces hormones produced in the body with synthetic hormones for the treatment of ailments like hormonal cancers, such as breast and prostate cancer, endometriosis and gender incongruence.

Both treatments are common, covered by the Pharmaceutical Benefits Scheme for cisgender patients, and have been used for decades.

Sign up for the Breaking News Australia email

The new NHMRC guidelines do not require a child be distressed to be treated for gender incongruence and recommend a multi-disciplinary team “should be determined on a case-by-case basis”.

Doctors should “prioritise the best interest and wellbeing of the young person and provide care that respects their autonomy”, the advice reads.

The guidelines describe gender incongruence as the clinical term for a difference between a person’s gender and their sex recorded at birth.

“It is not a mental health disorder,” it states.

“Some young people with gender incongruence will also experience significant distress, known as gender dysphoria.”

skip past newsletter promotion

after newsletter promotion

Puberty blockers have been used to treat children for a variety of conditions, such as precocious puberty, since the 1970s. They have been used in gender-affirming care since the 1990s.

The NHMRC advice largely aligns with the AusPATH Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy, Australia’s only existing guidelines for doctors.

The council is an independent statutory agency funded by the commonwealth. It is one of the world’s largest medical research organisations.

Its interim advice on puberty blocking drugs is based on advice from its multidisciplinary gender guideline development committee and “supported by a systematic review of the evidence”, the review said.

“Trans and gender-diverse young people experience unjust and avoidable health disparities arising from stigma, discrimination, and barriers to accessing health care,” it said.

Public consultation on the interim advice, called “Advice on the use of puberty suppressants in the care of trans and gender-diverse people aged under 18”, is open until 18 January.

The full guidelines will address other aspects of care, including the use of gender-affirming hormones, and are expected to be available in 2028.

Source: The Guardian · Andrew Messenger

At a glance

Topic
Politics
Country
🇬🇧 GB
Publisher language
EN
Added to Allnira